TransThera Sciences (Nanjing), Inc. (HKG:2617)

Market Cap	4.21B -79.5%
Revenue (ttm)	n/a
Net Income	-329.35M
EPS	-0.85
Shares Out	407.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,532,800
Open	10.44
Previous Close	10.38
Day's Range	10.12 - 10.44
52-Week Range	9.01 - 679.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About HKG:2617

TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a multi-kinase inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 123
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2617

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error